Dr Mike Jones – Managing Director – Impact Minerals (ASX:IPT) is an exploration company listed on the ASX in November 2006. The Company manages extensive tenement holdings (>4,000 km2) within Australia featuring significant potential for high-grade mineral deposits of gold, silver, lead, zinc, copper, nickel and PGM’s.
Copyright 2023 – Finance News Network
Source: Finance News Network
25 Sep 2023 - Wally Graham of Resources Roadhouse at the New World Metals Conference, speaking with Andy Tudor, Managing Director of Nexus Minerals (ASX:NXM).
Read More18 Oct 2019 - Calima Energy Limited (ASX:CE1) Managing Director, Alan Stein, talks about the company's strategy, recent capital raising, and results from the drill program at its Montney project.
Read More12 Nov 2024 - Dr Chris Burns, the CEO of NOVONIX Limited (ASX:NVX), shares details on a significant supply agreement with Stellantis for synthetic graphite, a milestone for the North American battery market.
Read More17 Aug 2020 - Elixinol Global (ASX:EXL) CEO & Executive Director, Oliver Horn talks about measures to reposition the business, initiatives in E-commerce and distribution, its decision to retain Hemp Foods Australia and outlook for Hemp and CBD based nutraceuticals.
Read More12 Mar 2025 - Sofdra's rollout and the path to $100m revenue
Read More03 May 2024 - US ban on Russian uranium imports could reshape the global market. Cauldron Energy's CEO Jonathan Fisher shares insights and implications for supply and prices.
Read More27 Aug 2021 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes provides an update on sales and distribution for the company's Automated Plate Assessment System (APAS), which is used to read culture plates in laboratories.
Read More26 Mar 2020 - Lithium Consolidated Mineral Exploration Limited (ASX:LI3) Managing Director Andrew Haythorpe provides an update on the company's new WA projects prospective for gold, nickel and base metals, board changes and plans to improve the company’s prospects.
Read More07 Jun 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's phase 1 trial results for its chlorotoxin CAR T (CLTX CAR T) cell therapy targeting glioblastoma.
Read More25 Mar 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt provides an update on the company's pipeline of clinical trials, focusing on results in head and neck cancer, lung cancer and breast cancer.
Read More
